Feroplus100 mg/5 ml

Feroplus is an oral iron salt used to replenish body iron stores. Its evidence-based indications are as follows:

Established/Approved Uses

• Treatment of iron-deficiency anemia confirmed or strongly suspected by laboratory findings (e.g., low serum ferritin, low hemoglobin/hematocrit with microcytic, hypochromic red cells).
• Prevention (prophylaxis) of iron-deficiency anemia in individuals at increased risk of iron deficiency, such as pregnant women, and people with chronic blood loss or inadequate dietary iron intake.

Guideline-Supported / Adjunct Uses

• As part of routine antenatal supplementation (often combined with folic acid) to reduce the risk of maternal anemia, in line with WHO antenatal care recommendations.
• As an adjunct in the management of anemia associated with chronic conditions where iron deficiency has been demonstrated (e.g., chronic kidney disease, chronic blood loss from gastrointestinal conditions), used alongside treatment of the underlying cause.

Feroplus is not indicated for anemias that are not due to iron deficiency (e.g., anemia of chronic disease without iron deficiency, hemolytic anemia, or megaloblastic anemia due to vitamin B12/folate deficiency alone), since iron will not correct these and may cause harmful iron accumulation.

Each formulation of Ferrous Fumarate provides elemental iron in the ferrous (Fe2+) form. Ferrous Fumarate contains approximately 33% elemental iron by weight, meaning a 200 mg tablet of Ferrous Fumarate supplies approximately 65-66 mg of elemental iron.

Ferrous Fumarate is available in various dosage forms including film-coated tablets, chewable tablets, oral drops, and oral liquid/syrup, often combined with folic acid or other B-vitamins in prenatal formulations. Exact strength and elemental iron content vary by brand and formulation; refer to the specific product label for precise values.

Feroplus is a hematinic agent (an iron-replacement salt) used in the treatment and prevention of iron-deficiency anemia. It belongs to the group of oral ferrous iron salts, which also includes ferrous sulfate and ferrous gluconate.

Iron is an essential trace mineral required for the synthesis of hemoglobin, myoglobin, and various enzymes involved in oxygen transport and cellular metabolism. When dietary intake or absorption of iron is insufficient to meet the body's needs, or when iron losses (e.g., from menstruation, pregnancy, or bleeding) exceed intake, iron-deficiency anemia can develop. Feroplus supplies supplemental elemental iron to correct this deficit and restore normal hemoglobin synthesis and iron stores.

Hematinic agents (oral iron/antianemic preparations); Feroplus belongs to the class of ferrous (Fe2+) iron salts.

Mechanism of Action

Ferrous Fumarate dissociates in the acidic environment of the stomach and upper small intestine to release ferrous (Fe2+) ions. These ions are absorbed primarily in the duodenum and proximal jejunum via the divalent metal transporter (DMT1) on enterocytes. Absorbed iron is either stored intracellularly as ferritin or transported into the bloodstream via ferroportin, where it binds to transferrin for delivery to the bone marrow and other tissues.

In the bone marrow, iron is incorporated into developing erythroblasts for hemoglobin synthesis, correcting the microcytic, hypochromic anemia characteristic of iron deficiency. Iron absorption is regulated by the body's iron status (increased absorption in deficiency states) and is influenced by dietary and pharmacological factors such as vitamin C (which enhances absorption) and calcium, antacids, and tannins (which reduce absorption).

Pharmacokinetics

Absorption of iron from Ferrous Fumarate is variable and dose-dependent, generally higher on an empty stomach but often limited by gastrointestinal tolerance. Unabsorbed iron is excreted in the feces (accounting for the characteristic dark stool color). Absorbed iron is conserved by the body and is lost only through minor routes such as desquamation of skin/mucosal cells, and physiological blood loss (e.g., menstruation), as the body has no active mechanism for iron excretion.

Take Feroplus preferably on an empty stomach for optimal absorption; if stomach upset occurs, it may be taken with a small amount of food (avoiding dairy, calcium supplements, antacids, tea, or coffee close to the dose). Do not take Feroplus at the same time as other medications known to interact with iron (see Drug Interactions) — separate by several hours. Use liquid formulations with the provided measuring device and consider using a straw to minimize tooth staining. Swallow tablets/capsules whole with water unless the product is specifically formulated to be chewed.

Feroplus can reduce the absorption of certain medications, and certain substances can reduce the absorption of Feroplus itself. Clinically significant interactions include:

• Levothyroxine: Feroplus can bind levothyroxine in the gut and reduce its absorption, potentially reducing thyroid hormone efficacy. Separate administration by at least 4 hours.
• Tetracyclines and fluoroquinolone antibiotics (e.g., doxycycline, ciprofloxacin): Iron chelates with these antibiotics, forming poorly absorbed complexes that reduce the efficacy of both the antibiotic and iron. Separate dosing by at least 2-3 hours.
• Levodopa/carbidopa: Iron can form complexes with levodopa, reducing its bioavailability and potentially reducing efficacy in Parkinson's disease management. Separate dosing.
• Antacids, calcium supplements, and proton pump inhibitors/H2 blockers: These raise gastric pH and/or compete for absorption, substantially reducing iron absorption from Feroplus. Separate dosing by at least 2 hours where possible.
• Tea, coffee, and high-phytate foods (e.g., bran, whole grains): Tannins and phytates bind iron and reduce its absorption; avoid taking Feroplus with these.
• Vitamin C (ascorbic acid): Enhances absorption of iron from Feroplus by keeping it in the more absorbable ferrous state; may be used deliberately to improve absorption.

The most common side effects of Feroplus are gastrointestinal and are generally dose-related:

• Nausea, epigastric discomfort or pain
• Constipation (most common) or, less often, diarrhea
• Dark or black-colored stools — this is an expected, harmless effect of unabsorbed iron and should not be confused with melena (tarry, foul-smelling stools indicating gastrointestinal bleeding); consult a physician if there is uncertainty or accompanying symptoms such as abdominal pain or blood in stool.
• Temporary staining of teeth with liquid formulations if not properly administered

Less common effects include heartburn and, rarely, hypersensitivity reactions. If severe abdominal pain, vomiting, or signs of an allergic reaction occur, discontinue and seek medical advice.

Pregnancy: Iron requirements increase during pregnancy, and Feroplus is commonly used, at recommended doses, for prevention and treatment of iron-deficiency anemia in pregnancy as part of routine antenatal care. As with any medication in pregnancy, Feroplus should be used only as directed by a physician, who will weigh the well-established benefit of correcting iron deficiency against any individual risk factors; use only if clearly needed and as advised, since excessive iron intake beyond recommended doses is not advised.

Lactation: Feroplus is generally considered compatible with breastfeeding when used at recommended doses, as iron transfer into breast milk is minimal and not expected to affect the infant. Consult a physician before use during breastfeeding, particularly regarding dose and duration.

• Accidental pediatric poisoning: Iron-containing products, including Feroplus, are a leading cause of accidental fatal poisoning in young children. Keep all iron products out of the reach and sight of children, and store in child-resistant packaging.
• Gastrointestinal conditions: Use with caution in patients with active peptic ulcer disease, ulcerative colitis, or other inflammatory bowel disease, as iron can irritate the gastrointestinal mucosa and may worsen symptoms; a physician should weigh the need for iron therapy against potential GI irritation in these patients.
• GI tolerability: Gastrointestinal side effects (constipation, nausea) are common; taking Feroplus with a small amount of food may help if upset occurs, although this may reduce absorption (see Side Effects).
• Drug interactions: Several medications have reduced absorption when taken with Feroplus; separate dosing as advised (see Drug Interactions).
• Stool discoloration: Dark/black stools are expected and harmless; distinguish from true melena in the appropriate clinical context (see Side Effects).
• Monitoring: Periodic monitoring of hemoglobin and iron studies (e.g., serum ferritin) is recommended to confirm response and avoid unnecessary prolonged use or iron overload, particularly in patients with hereditary hemochromatosis carrier status or other risk factors.

Overdose of Feroplus (iron poisoning) is a recognized medical emergency, especially in young children, and can be life-threatening even with a relatively small number of tablets. Early symptoms (within hours) may include nausea, vomiting, abdominal pain, and diarrhea (which may be bloody); this can be followed by a deceptively symptom-free period, then progress to metabolic acidosis, lethargy, shock, liver damage, and, in severe cases, cardiovascular collapse and death.

If overdose of Feroplus is suspected, seek immediate emergency medical attention or contact a poison control center right away — do not wait for symptoms to appear. Do not attempt to treat iron overdose at home; hospital management (which may include specific chelation therapy) is required and is time-critical.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children, in a child-resistant container, as iron products are a leading cause of accidental pediatric poisoning.

• Pregnant women: Commonly used at recommended prophylactic or treatment doses under medical supervision (see Pregnancy and Lactation).
• Elderly: No specific dose adjustment is well established, but the elderly may be more susceptible to constipation and other GI effects; monitor and manage tolerability. Screen for and evaluate the underlying cause of iron deficiency, as gastrointestinal blood loss is more common in this age group.
• Renal impairment: No specific well-established dose adjustment for oral Feroplus; iron needs and formulation choice (oral versus parenteral) in chronic kidney disease/dialysis should be individualized by a physician.
• Hepatic impairment: No specific well-established dose adjustment; use with caution given the liver's role in iron storage and metabolism.
• Hereditary hemochromatosis (carriers) or family history of iron overload: Use with caution and appropriate monitoring; Feroplus is contraindicated in overt iron overload disorders (see Contraindications).

For treatment of iron-deficiency anemia, Feroplus is typically continued for approximately 3-6 months after hemoglobin has normalized, in order to replenish depleted iron stores (ferritin), and duration should be guided by a physician based on laboratory response. For prophylactic use (e.g., in pregnancy), Feroplus is generally continued throughout the period of increased iron requirement, as advised by a physician or antenatal care provider.

Hematinics; oral ferrous iron salts; antianemic/iron-replacement agents. Ferrous Fumarate is one of several ferrous iron salts used therapeutically (others include ferrous sulfate and ferrous gluconate).

Ferrous Fumarate releases ferrous (Fe2+) ions that are absorbed in the duodenum and proximal jejunum and used by the bone marrow to synthesize hemoglobin, correcting iron-deficiency anemia and replenishing body iron stores (see Pharmacology for full mechanistic detail).

A

Feroplus may be used in children for the treatment or prevention of iron-deficiency anemia, generally with a liquid, drop, or chewable formulation appropriate for the child's age, and dosed on a weight basis (elemental iron mg/kg/day) as advised by a pediatrician. Typical pediatric treatment doses range from approximately 3-6 mg/kg/day of elemental iron in divided doses, though the exact dose, formulation, and duration should always be determined by a physician based on the child's age, weight, and degree of deficiency.

Safety and efficacy of specific fixed-dose combination products containing Feroplus have not been established in all pediatric age groups; use only the formulation and dose advised by a pediatrician. Iron products, including Feroplus, must be stored safely out of children's reach, as accidental ingestion is a leading cause of pediatric poisoning and can be fatal even in small amounts relative to a child's body weight (see Overdose and Precautions).